business
Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3
Tyra Biosciences prices a $400 million underwritten offering on Monday to advance its precision medicine programs targeting fibroblast growth factor receptor biology.
Read full article on Rttnews